Hawaii Bill: HB 717

Bill Summary

This establishes a KCPA-aligned framework requiring registration, third-party testing, labeling with alkaloid content, age restrictions (under 18), and prohibitions on adulterated or synthetic products—matching FDA guidance by distinguishing safe natural kratom from dangerous compounds while maintaining consumer access through responsible regulation.

Why it matters to MAHA

HI HB717 models the consumer-protection approach MAHA supports: empowering informed choice through transparency and testing rather than prohibition. It aligns with FDA's July 2025 guidance by targeting dangerous synthetics while preserving kratom access, and follows successful KCPA implementations in Colorado, Oklahoma, and Mississippi—demonstrating health freedom and state autonomy.